Patient Leaflet Updated 04-Jul-2024 | ADVANZ Pharma
Deferiprone 500mg Film-coated Tablets
Deferiprone 500mg film-coated tablets
Deferiprone 1000mg film-coated tablets
deferiprone
1. What Deferiprone tablets are and what they are used for
2. What you need to know before you take Deferiprone tablets
3. How to take Deferiprone tablets
4. Possible side effects
5. How to store Deferiprone tablets
6. Contents of the pack and other information
Deferiprone film-coated tablets (called Deferiprone tablets throughout the rest of this leaflet) contain the active substance deferiprone. Deferiprone is an iron chelator, a type of medicine that removes excess iron from the body.
Deferiprone tablets are used to treat iron overload caused by frequent blood transfusions in patients with thalassaemia major when current chelation therapy is contraindicated or inadequate.
Talk to your doctor or pharmacist before taking Deferiprone tablets:
Your doctor will also ask you to come in for tests to monitor body iron load. In addition, he or she might ask you to undergo liver biopsies.
Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other medicines.
Do not take medicines known to cause low white blood cell count (neutropenia) or agranulocytosis (see “Do not take Deferiprone tablets”). Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other medicines, including medicines obtained without a prescription.
Do not take aluminium-based antacids at the same time as taking Deferiprone tablets.
Please consult with your doctor or pharmacist before taking Vitamin C with Deferiprone tablets.
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor, nurse or pharmacist for advice before taking this medicine.
Deferiprone tablets may cause harm to unborn babies when used by pregnant women. Deferiprone tablets must not be used during pregnancy unless clearly necessary. If you are pregnant or you become pregnant during treatment with Deferiprone tablets, get medical advice immediately.
Both female and male patients are recommended to take special precautions in their sexual activity if there is any possibility for pregnancy to occur: Women of childbearing potential are recommended to use effective contraception during treatment with Deferiprone tablets and for 6 months after the last dose. Men are recommended to use effective contraception during treatment and for 3 months after the last dose. This should be discussed with your doctor.
Do not use Deferiprone tablets if you are breastfeeding. Please refer to the patient card attached to the leaflet.
Not relevant.
Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.
There are limited data available on the safety of deferiprone tablets in children. If the doctor decides that your child needs this medicine, they will determine the most appropriate dose to give.
There are no reports of acute overdose with Deferiprone tablets. If you have accidentally taken more than the prescribed dose, you should contact your doctor.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
The most serious side effect of Deferiprone tablets is a very low white blood cell (neutrophil) count. This condition, known as severe neutropenia or agranulocytosis, has occurred in 1 to 2 out of 100 people who have taken deferiprone in clinical studies. A low white blood count can be associated with a serious and potentially life-threatening infection. Report immediately to your doctor any symptoms of infection such as fever, sore throat or flu-like symptoms.
Very common side effects (may affect more than 1 in 10 people)
If you experience nausea or vomiting, it may help to take your Deferiprone tablets with some food. Discoloured urine is a very common effect and is not harmful.
Common side effects (may affect up to 1 in 10 people)
Not known (frequency cannot be estimated from the available data)
Events of joint pain and swelling ranged from mild pain in one or more joints to severe disability. In most cases, the pain disappeared while patients continued taking Deferiprone tablets .
Neurological disorders (such as tremors, walking disorders, double vision, involuntary muscle contractions, problems with movement coordination) have been reported in children who had been voluntarily prescribed more than double the maximum recommended dose of 100 mg/kg/day for several years and have also been observed in children with standard doses of deferiprone. The children recovered from these symptoms after Deferiprone tablets discontinuation.
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.
By reporting side effects, you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date stated on the carton and blister or label. The expiry date refers to the last day of that month.
This medicinal product does not require any special storage conditions.
If you have been prescribed Deferiprone tablets in a plastic bottle, you should use the tablets within 70 days, once the bottle has been opened.
If you have been prescribed Deferiprone tablets in a blister strip, and you have a half tablet, you should push this back into the blister pocket, and store the blister strip in the original carton until it is time for your next dose or for a maximum of 48 hours.
Do not use this medicine if you notice any visible signs of deterioration of the blister pack or the tablets. Return it to your pharmacist.
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help to protect the environment.
Deferiprone 500mg tablets are white to off-white film-coated tablets with a score line on one side and plain on the other. Tablets can be divided into equal halves.
Deferiprone 500mg tablets may be supplied in blister packs or plastic bottles of 100 tablets.
Deferiprone 1000mg tablets are white to off-white film-coated tablets with a score line on one side and plain on the other. Tablets can be divided into equal halves.
Deferiprone 1000mg tablets may be supplied in blister packs of 50 tablets or plastic bottles of 50 or 100 tablets.
Not all pack sizes may be marketed.
For any information about this medicinal product, please contact the Marketing Authorisation Holder, details provided above.
This leaflet was last revised in June 2024.
((Front Cover))
Important Safety Reminders for Patients taking Deferiprone tablets
Prescribing doctor:
Phone No:
((Back Cover))
FOR WOMEN OF CHILDBEARING AGE
Do not take Deferiprone tablets if you are pregnant or if you are trying to become pregnant. If taken during pregnancy, Deferiprone tablets may seriously harm the unborn baby.
You must use effective contraception while you are taking Deferiprone tablets. Ask your doctor which method is best for you. If you become pregnant while taking Deferiprone Tablets, stop taking the medicine immediately and tell the doctor. Do not take Deferiprone tablets if you are breastfeeding.
((Inside 1))
MONITORING YOUR WHITE BLOOD CELL COUNT WITH DEFERIPRONE TABLETS
There is a small chance that you may develop agranulocytosis (very low white blood cell count) while taking Deferiprone tablets, which may lead to a serious infection. Even though agranulocytosis only affects 1 to 2 out of 100 users, it is important to monitor your blood on a regular basis.
((Inside 2))
Make sure you do the following:
1. Have your blood monitored on a weekly basis.
2. Contact your doctor immediately if you develop a fever, sore throat or flu-like symptoms.
Dashwood House, 69 Old Broad Street, London, EC2M 1QS, UK
+44 (0)208 588 9131
www.advanzpharma.com
+44 (0)208 588 9131
+44 (0)208 588 9273